Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA meeting rescheduled

This article was originally published in The Tan Sheet

Executive Summary

Manufacturing Subcommittee of the Advisory Committee on Pharmaceutical Science, which was slated to meet March 21, will instead combine that agenda with next scheduled meeting May 21-22. Inaugural meeting of the subcommittee was cancelled due to war in Iraq; FDA was expected to outline its progress on the "Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach" initiative (1"The Tan Sheet" Sept. 2, 2002, p. 13)...

You may also be interested in...



Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record

FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities

2020 Sees Sharp Rise In EU New Drug Approvals

The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.

Canada Proposes 14 New Entries To List Of Recognized Device Standards

The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel